Women's Health
Commentary
Cesarean Delivery and Hospitals: Size Matters
Original Research
Differences in Institutional Cesarean Delivery Rates: The Role of Pain Management
Clinical Inquiries
When should we stop mammography screening for breast cancer in elderly women?
EVIDENCE-BASED ANSWER: There is insufficient evidence to recommend for or against routine screening mammography beyond the age of 69 years. The...
Clinical Inquiries
Is there any benefit to Papanicolaou (Pap) test screening in women who have had a hysterectomy for benign disease?
EVIDENCE-BASED ANSWER: The primary motivation to screen asymptomatic women after a hysterectomy is to prevent morbidity and mortality from...
Original Research
Routine Screening for Postpartum Depression
Original Research
The Role of Gynecologists in Providing Primary Care to Elderly Women
Q&A
Should breech babies be delivered vaginally or by planned cesarean delivery?
Hannah ME, Hannah WJ, Hewson SA, Hodnett ED, Saigal S, Willan AR. Planned caesarean section versus planned vaginal birth for breech presentation...
Q&A
Are there adverse maternal and neonatal outcomes associated with induction of labor when there is no well-accepted indication?
Dublin S, Lydon-Rochelle M, Kaplan RC, Watts DH, Critchlow CW. Maternal and neonatal outcomes after induction of labor without an identified...
Q&A
What is the risk of venous thromboembolism (VTE) among women taking third-generation oral contraceptives (OCs) in comparison with those taking contraceptives containing levonorgestrel?
Jick H, Kaye JA, Vasilakis-Scaramozza C, Jick SS. Risk of venous thromboembolism among users of third generation oral contraceptives compared with...
Q&A
Does the increased sensitivity of the new Papanicolaou (Pap) tests improve the cost-effectiveness of screening for cervical cancer?
Myers ER, McCrory DC, Subramanian S, et al. Setting the target for a better cervical screening test: characteristics of a cost-effective test for...
Q&A
Can vaginal misoprostol be administered 1 to 3 days after mifepristone without loss of efficacy or an increase in adverse events?
Schaff EA, Fielding SL, Westhoff C, et al. Vaginal misoprostol administered 1, 2, or 3 days after mifepristone for early medical abortion: a...